243 related articles for article (PubMed ID: 29692982)
1. Oncogenes in immune cells as potential therapeutic targets.
Zakiryanova GK; Wheeler S; Shurin MR
Immunotargets Ther; 2018; 7():21-28. PubMed ID: 29692982
[TBL] [Abstract][Full Text] [Related]
2. Role of proto-oncogene activation in carcinogenesis.
Anderson MW; Reynolds SH; You M; Maronpot RM
Environ Health Perspect; 1992 Nov; 98():13-24. PubMed ID: 1486840
[TBL] [Abstract][Full Text] [Related]
3. Different pattern of expression of cellular oncogenes in human non-small-cell lung cancer cell lines.
Kiefer PE; Wegmann B; Bacher M; Erbil C; Heidtmann H; Havemann K
J Cancer Res Clin Oncol; 1990; 116(1):29-37. PubMed ID: 1690210
[TBL] [Abstract][Full Text] [Related]
4. Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation.
Liebermann DA; Hoffman B
Stem Cells; 1994 Jul; 12(4):352-69. PubMed ID: 7951003
[TBL] [Abstract][Full Text] [Related]
5. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
6. Alterations of oncogenes expression in NK cells in patients with cancer.
Zakiryanova GK; Kustova E; Urazalieva NT; Amirbekov A; Baimuchametov ET; Nakisbekov NN; Shurin MR
Immun Inflamm Dis; 2017 Dec; 5(4):493-502. PubMed ID: 28695716
[TBL] [Abstract][Full Text] [Related]
7. Oncogenes and cell death.
Harrington EA; Fanidi A; Evan GI
Curr Opin Genet Dev; 1994 Feb; 4(1):120-9. PubMed ID: 8193531
[TBL] [Abstract][Full Text] [Related]
8. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
9. The molecular genetics of human lung cancer.
Slebos RJ; Rodenhuis S
Eur Respir J; 1989 May; 2(5):461-9. PubMed ID: 2547647
[TBL] [Abstract][Full Text] [Related]
10. Oncogene activation and tumor suppressor gene inactivation during multistage mouse skin carcinogenesis.
Bowden GT; Schneider B; Domann R; Kulesz-Martin M
Cancer Res; 1994 Apr; 54(7 Suppl):1882s-1885s. PubMed ID: 8137304
[TBL] [Abstract][Full Text] [Related]
11. Role of oncogenes and tumour suppressor genes in human lung carcinogenesis.
Harris CC; Reddel R; Pfeifer A; Iman D; McMenamin M; Trump BF; Weston A
IARC Sci Publ; 1991; (105):294-304. PubMed ID: 1855868
[TBL] [Abstract][Full Text] [Related]
12. Gene amplification in human lung cancer. The myc family genes and other proto-oncogenes and growth factor genes.
Bergh JC
Am Rev Respir Dis; 1990 Dec; 142(6 Pt 2):S20-6. PubMed ID: 2174659
[TBL] [Abstract][Full Text] [Related]
13. Basic research in prostate cancer: molecular biology.
Effert PJ; Strohmeyer TG
Acta Urol Belg; 1994 Apr; 62(1):15-21. PubMed ID: 8197925
[TBL] [Abstract][Full Text] [Related]
14. Oncogenes and tumor progression.
Muschel RJ; McKenna WG
Anticancer Res; 1989; 9(5):1395-406. PubMed ID: 2686535
[TBL] [Abstract][Full Text] [Related]
15. Macrophage priming and activation during fibrosarcoma growth: expression of c-myb, c-myc, c-fos, and c-fms.
Alleva DG; Askew D; Burger CJ; Elgert KD
Immunol Invest; 1994 Nov; 23(6-7):457-72. PubMed ID: 7851963
[TBL] [Abstract][Full Text] [Related]
16. Molecular analysis of oncogenes, ras family genes (N-ras, K-ras, H-ras), myc family genes (c-myc, N-myc) and mdm2 in natural killer cell neoplasms.
Sugimoto KJ; Kawamata N; Sakajiri S; Oshimi K
Jpn J Cancer Res; 2002 Nov; 93(11):1270-7. PubMed ID: 12460470
[TBL] [Abstract][Full Text] [Related]
17. Cadmium-induced cell transformation and tumorigenesis are associated with transcriptional activation of c-fos, c-jun, and c-myc proto-oncogenes: role of cellular calcium and reactive oxygen species.
Joseph P; Muchnok TK; Klishis ML; Roberts JR; Antonini JM; Whong WZ; Ong T
Toxicol Sci; 2001 Jun; 61(2):295-303. PubMed ID: 11353138
[TBL] [Abstract][Full Text] [Related]
18. MYC: Master Regulator of Immune Privilege.
Casey SC; Baylot V; Felsher DW
Trends Immunol; 2017 Apr; 38(4):298-305. PubMed ID: 28233639
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic co-operation in beta-cell tumorigenesis.
Pelengaris S; Khan M
Endocr Relat Cancer; 2001 Dec; 8(4):307-14. PubMed ID: 11733227
[TBL] [Abstract][Full Text] [Related]
20. Activated oncogenes and putative tumor suppressor genes involved in human breast cancers.
Tripathy D; Benz CC
Cancer Treat Res; 1992; 63():15-60. PubMed ID: 1363356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
